Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Tovecimig-Based Doublet Boosts Response and PFS in Advanced Biliary Tract Cancer

(MedPage Today) -- Investigational tovecimig combined with paclitaxel significantly improved the response rate and progression-free survival (PFS) in patients with previously treated advanced or metastatic biliary tract cancer, according to the...

Tovecimig-Based Doublet Boosts Response and PFS in Advanced Biliary Tract Cancer

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Saturday 24 October →